Pillar Guide
Peptide Therapy: Complete Guide to Physician-Supervised Peptides
GLP-1, growth-hormone peptides, regenerative peptides — explained by a physician.
The short answer: Peptide therapy is the use of short amino-acid chains as targeted signaling molecules — distinct from full hormones or small-molecule drugs. The most evidence-supported peptides in 2026 are the GLP-1 agonists (semaglutide, tirzepatide) for weight and metabolic care, sermorelin and CJC-1295/ipamorelin for growth-hormone optimization, BPC-157 for tissue regeneration, and PT-141 for libido. All require physician evaluation, lab work, and ongoing supervision.
Comparison table — peptide, category, evidence, route
| Peptide | Category | Evidence | Route |
|---|---|---|---|
| Semaglutide | GLP-1 agonist | FDA-approved | Weekly subcutaneous |
| Tirzepatide | Dual GIP/GLP-1 agonist | FDA-approved | Weekly subcutaneous |
| Retatrutide | Triple agonist (GIP/GLP-1/glucagon) | Phase 3 trials | Weekly subcutaneous |
| Sermorelin | Growth hormone-releasing peptide | Off-label, decades of use | Daily subcutaneous |
| CJC-1295 + Ipamorelin | GHRH analog + ghrelin mimetic | Off-label compounded | Daily subcutaneous |
| BPC-157 | Pentadecapeptide (regenerative) | Animal + early clinical | Oral or subcutaneous |
| PT-141 (Bremelanotide) | Melanocortin agonist | FDA-approved (HSDD) | Subcutaneous as needed |
| AOD-9604 | GH fragment 176-191 | Early clinical | Daily subcutaneous |
| GHK-Cu | Copper-peptide complex | Topical: strong; systemic: limited | Topical or subcutaneous |
What is Semaglutide?
Semaglutide is a GLP-1 receptor agonist FDA-approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). It slows gastric emptying, reduces appetite, and produces 12–15% average body-weight loss over 68 weeks in clinical trials. Compounded semaglutide expands access while branded supply is constrained; kindr Health prescribes both branded and compounded forms after physician evaluation.
What is Tirzepatide?
Tirzepatide is a dual GIP and GLP-1 receptor agonist FDA-approved as Mounjaro (diabetes) and Zepbound (weight). The dual mechanism produces higher average weight loss than semaglutide — roughly 20% at 72 weeks at the 15 mg dose — with a similar gastrointestinal side-effect profile.
What is Retatrutide?
Retatrutide is an investigational triple agonist showing the largest weight-loss results to date — up to 24% in Phase 2 trials. Not yet FDA-approved; kindr Health does not prescribe retatrutide. This page is informational while approval is pending.
What is Sermorelin?
Sermorelin stimulates the pituitary to release endogenous growth hormone in a physiological pulsatile pattern. Used off-label for body-composition support, recovery, and sleep quality in adults over 35 with documented GH decline.
What is CJC-1295 + Ipamorelin?
A combination of a long-acting GHRH analog (CJC-1295) and a selective growth hormone secretagogue (ipamorelin). Produces larger GH release than sermorelin without significantly raising cortisol or prolactin.
What is BPC-157?
BPC-157 is a 15-amino-acid fragment derived from gastric juice with strong preclinical data for tendon, ligament, gut, and vascular healing. Human clinical data is early-stage; use is off-label.
What is PT-141 (Bremelanotide)?
PT-141 (bremelanotide) is a melanocortin receptor agonist FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women. Used off-label in postmenopausal women and men for libido support.
What is AOD-9604?
AOD-9604 is a modified C-terminal fragment of growth hormone studied for fat metabolism without GH’s growth or insulin effects. Clinical evidence is mixed; positioned as adjunctive only.
What is GHK-Cu?
GHK-Cu is a tripeptide-copper complex with extensive cosmetic-dermatology evidence for skin remodeling and hair-follicle support. Subcutaneous use is off-label and less well-studied.
Who is eligible for peptide therapy?
Adults 18 and older with a clinical indication after physician evaluation. Pre-prescription requirements at Kindr Health: a brief medical history, baseline labs appropriate to the peptide (CBC, CMP, lipid panel, A1c, IGF-1 for GH peptides), and an asynchronous or synchronous physician consultation. Pregnancy, active malignancy, and uncontrolled endocrine disease are contraindications for most peptides.
Frequently asked questions
Are peptide therapies FDA-approved?
Some — semaglutide (Ozempic/Wegovy), tirzepatide (Mounjaro/Zepbound), and bremelanotide (Vyleesi) are FDA-approved. Sermorelin was previously approved for pediatric GH deficiency. CJC-1295, ipamorelin, BPC-157, AOD-9604, and GHK-Cu are used off-label and dispensed via compounding pharmacies under physician supervision.
How is peptide therapy delivered?
Most peptides are dispensed as subcutaneous injections in small-volume vials with insulin syringes. Some (PT-141, BPC-157 oral) have alternative routes. Every kindr Health peptide order ships with full instructions and a physician-supervised onboarding.
Who is a candidate for peptide therapy?
Adults 18+ with clear clinical indication after physician evaluation. Pregnancy, active cancer, and certain endocrine conditions are contraindications. A kindr Health clinician reviews labs and history before any prescription is issued.
How long until peptides work?
GLP-1 weight loss begins in 2–4 weeks. Sermorelin and CJC/Ipamorelin sleep effects appear in 1–2 weeks; body-composition changes take 3–6 months. BPC-157 tissue-healing effects are typically measured at 4–8 weeks. PT-141 acts within hours of injection.
Are peptides safe to combine with HRT?
Generally yes. GLP-1s, sermorelin, CJC/Ipamorelin, and BPC-157 do not have clinically meaningful interactions with estradiol, progesterone, or testosterone. A kindr Health physician reviews the full medication list before prescribing.
How much does peptide therapy cost?
Compounded semaglutide and tirzepatide programs start around $199–$399/month; growth-hormone peptides $250–$500/month; PT-141 priced per dose. kindr Health publishes transparent pricing on every product page.
Medically reviewed by Kindr Health Clinical Team, Kindr Health Inc. clinical oversight (Organizational NPI 1609792902). Last reviewed 2026-06-10. All peptide prescriptions require physician evaluation and ongoing monitoring at Kindr Health.
Latest from the Journal
Evidence & Policy
Why hormone therapy is still underused, 24 years after the WHI
One 2002 press conference reshaped a generation of care. Here is what the Women’s Health Initiative actually found, what was misread, and where the guidelines stand now.
Read Why hormone therapy is still underused, 24 years after the WHI →
Metabolic Menopause
Metabolic menopause: why your metabolism changes and what actually works
Estrogen loss reshapes insulin sensitivity, fat distribution, and mitochondrial function. Here is what "metabolic menopause" really means — and the protocol that reverses it.
Read Metabolic menopause: why your metabolism changes and what actually works →
Metabolic Menopause
Insulin resistance in perimenopause: the earliest warning sign most doctors miss
Fasting insulin rises years before fasting glucose. Here is how to catch perimenopausal insulin resistance early and reverse it.
Read Insulin resistance in perimenopause: the earliest warning sign most doctors miss →